Flowsense device detects kidney damage

Flowsense's share price fell 10.8% by early afternoon to a market cap of NIS 30 million.

Flowsense Medical Ltd. (TASE: FLSN) today announced that a clinical trial of its Urinflo 2000 device detected early-stage acute kidney damage

The trial of 25 patients at the San Bortolo Hospital in Vicenza, Italy, was conducted by Prof. Claudio Ronco, an international expert in the critical care nephrology

Flowsense says that 5% of patients in hospital and 30% of patients in intensive care wards suffer from acute kidney damage, which increases morbidity rates and the cost of care.

Flowsense's share price fell 10.8% by early afternoon to NIS 0.12, giving a market cap of NIS 30 million.

Published by Globes [online], Israel business news - www.globes-online.com - on March 6, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018